Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 1999

View Archived Issues

Patent protection received for newest addition to Molecular Biosystems' pipeline

Neurocrine discontinues development of DHEA; to advance other programs

Epicoat technology granted U.S. patent protection

Celgene and NCI collaborate on thalidomide study in glioblastoma

FDA ruling upholds orphan drug exclusivity for Avonex

Two Boehringer Ingelheim drugs to be copromoted by Abbott in U.S.

Wyeth-Ayerst and Neurocrine to develop drugs targeting neurotransmitter transporters

Wyeth-Ayerst to market Abelcet in the U.K.

Ontogeny establishes research collaborations for skin cancer therapy

Medtronic and Cognetix to develop new treatment for epilepsy

Rhone-Poulenc Rorer describes new hypoglycemic series

Antiulcer PGE analogues developed at Taisho

Taisho scientists isolate and and characterize new antifungal agent

New Astra compounds for the therapy of 5-HT-mediated disorders

Prokinetic and analgesic benzamides developed at French laboratory

MGI-114 in combination with CPT-11 enters clinical evaluation

Randomized comparison of aspirin, aspirin + warfarin and aspirin + ticlopidine following stenting

MMP inhibitor-chemotherapeutic drug combination suppresses tumor dissemination in mice

Gene therapy with human HGF proves simple, safe and effective in rats with cirrhosis

Toagosei researchers identify potent antitumor MAb

Lilly delays phase III clinical trials of migraine compound

FDA advisory committee declines to recommend approval of Locilex

Licensing opportunity from BTG: fatty acid-peptide conjugates for use in vaccines

Single-isomer version of epilepsy Rx developed at ABS

Available for licensing from BTG: immune function modulator with applications in dermatology

GenoPlex licenses rights to AD discoveries from MGH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...